CG MedTech Co

CG MedTech Co Net Debt / EBITDA

The Net Debt to EBITDA of CG MedTech Co (056090.KQ) as of Oct 18, 2026 is 0.23. In the previous year, Net Debt to EBITDA was -4.40 — a change of -105.12% (higher).

Net Debt / EBITDA

0.23

YoY

-105.12%

Last updated:

Net Debt to EBITDA of CG MedTech Co is 2025 0.23 . Net Debt to EBITDA of CG MedTech Co was 2024 -4.40 . It decreases by -105.12% higher compared to the previous year.

The CG MedTech Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
1.81 KRW
Jan 1, 2018
-0.89 KRW
Jan 1, 2019
-33.05 KRW
Jan 1, 2020
-1.38 KRW
Jan 1, 2021
-2.32 KRW
Jan 1, 2022
52.68 KRW
Jan 1, 2024
-4.40 KRW
Jan 1, 2025
0.23 KRW
The CG MedTech Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.23-105.12%
-4.40-108.36%
52.68-2,371.91%
-2.32+68.64%
-1.38-95.84%
-33.05+3,603.12%
-0.89-149.43%
1.81-79.04%
8.61-224.42%
-6.92-210.87%
6.24-28.45%
8.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG MedTech Co Stock analysis

What does CG MedTech Co do? CG MedTech Co Ltd, listed on the Korea Exchange with ticker 056090.KQ and ISIN KR7056090004, is a company based in Uijeongbu, South Korea. It operates within the Health Care sector, specifically in the Health Care industry. The company went public on November 12, 2015. Its website is https://inno-sys.net/. CG MedTech Co Ltd focuses on the manufacture of orthopaedic surgical implants and surgical devices. The company's business activities are conducted through two segments: the Medical Device Business segment, which involves the production and sale of spinal fixation devices, micro-invasive medical devices for back pain treatment, fracture treatment devices, and bioabsorbable alloy implants, and the Electric Energy Business segment, which is involved in the production and sale of electricity meters and integrated calorimeters. The company's headquarters are located in Uijeongbu, Gyeonggi-Do. The website provided is associated with the company, though the source description mentions 'Innosys Co. Ltd.' as the company name, which may differ from the official name. The source also indicates that the company's IPO date is November 12, 2015, which aligns with the provided information. The company's operations are centered around medical devices, with a secondary focus on electric energy products. CG MedTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG MedTech Co stock

Net Debt to EBITDA of CG MedTech Co is 0.23 in 2025.

Net Debt to EBITDA of CG MedTech Co changed from -4.40 to 0.23, representing a -105.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA CG MedTech Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's CG MedTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CG MedTech Co

All Key Metrics — CG MedTech Co